<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988776</url>
  </required_header>
  <id_info>
    <org_study_id>PECS II versus ICBN block</org_study_id>
    <nct_id>NCT04988776</nct_id>
  </id_info>
  <brief_title>PECS II Versus ICBN Block Plus SCNB for AV Fistula Creation in CRF Patients</brief_title>
  <official_title>Comparison Between Ultrasound-guided Pectoral Nerves Block Type II and Intercostobrachial Nerve Block as a Supplement to Supraclavicular Block for Anesthesia of Proximal Arteriovenous Access in End-stage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mamdoh Elsayed Lotfy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>amany aly sultan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>reem gaber abdel-mageed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brachial plexus block (BPB) is often utilized for proximal arm arteriovenous access creation.&#xD;
      However, the medial upper arm and axilla are often inadequately anesthetized, as the&#xD;
      Intercostobrachial nerve (which provides sensory supply to the axilla, upper medial arm, and&#xD;
      a small area at the upper lateral chest) is not a component of the brachial plexus. This&#xD;
      requires repeated, an intraoperative local anesthetic (LA) supplementation up to conversion&#xD;
      into GA. The intercostobrachial nerve (ICBN) is a purely sensory nerve that arises primarily&#xD;
      from the second intercostal nerve (T2) with occasional contribution from T3. Therefore, It is&#xD;
      not a component of the brachial plexus and is not anesthetized by brachial plexus blockade.&#xD;
      The ICBN can be blocked together with other nerves, such as the pectoral, intercostal, and&#xD;
      long thoracic nerves in a recently described technique named pectoral nerves block type II&#xD;
      (PECS II ).In this thesis, investigators compared the use of the PECS II block and ICBN block&#xD;
      as a supplement to supraclavicular brachial plexus block for providing complete anesthesia of&#xD;
      the upper arm for fistula creation surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraoperative local anesthetic requirement</measure>
    <time_frame>1-2 hours after surgery start</time_frame>
    <description>volume of local anesthetic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Visual analogue score (0-10) where 0=no pain and 10=the worst pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Intraoperative Analgesia</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m</intervention_name>
    <description>patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block</intervention_name>
    <description>Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )</description>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ESRD patients.&#xD;
&#xD;
          -  Proximal Arm Arteriovenous Access Surgery.&#xD;
&#xD;
          -  Elective or emergency surgery&#xD;
&#xD;
          -  American Society of Anesthesiology (ASA) physical status II to III.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability of the patient to provide informed consent, communicate or cooperate&#xD;
&#xD;
          -  History of allergy to local anesthetics.&#xD;
&#xD;
          -  Preexisting upper limb neurological disease at the side of the surgery.&#xD;
&#xD;
          -  Patients on anticoagulant therapy or with history of coagulopathy.&#xD;
&#xD;
          -  Previous surgery at or near the site of the study.&#xD;
&#xD;
          -  The presence of skin infection at the puncture site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>reem abdel-mageed, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>resident of anesthesia, menoufia university hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ashraf Magdy Eskandr</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <state>Menoufia</state>
        <zip>32951</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>ashraf magdy eskandr</investigator_full_name>
    <investigator_title>assistant professor of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be available after end of the study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>for 1 year after the end of the study</ipd_time_frame>
    <ipd_access_criteria>study protocol</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

